				_	$\overline{}$
Please type a	plus sign	(+)	inside this box		+

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Vi Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY **PATENT APPLICATION TRANSMITTAL**

KOJIM-436 Attorney Docket No. Jun HATAKEYAMA et al. First Inventor AMINE COMPOUNDS, RESIST COMPOSITIONS AND PATTERNING PROCESS

(Only for ne	ew nonprovisional	applications under	37 C.F.R. 1.53(b))) [E	xpress Mail L	abel No.				ر ه	
	APPLICATION ELEMENTS						ASSISTANT Commissioner for Patents Box Patent Application ASSISTANT COMMISSIONER FOR PATENTS OF THE PROPERTY OF THE PATENTS OF THE PATENTS				
See MPEP chapter 600 concerning utility patent application contents. 1. Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Applicant claims small entity status. See 37 CFR 1.27. 3. Specification [Total Pages 78] [(preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure						Washington, DC 20231 7. □ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. □ Computer Readable Form (CRF) b. Specification Sequence Listing on: i. □ CD-ROM or CD-R (2 copies); or ii. □ paper c. □ Statements verifying identity of above copies ACCOMPANYING APPLICATIONS PARTS 9. ☑ Assignment Papers (cover sheet & document(s)) 10. □ 37 C.F.R.§3.73(b) Statement □ Power of (when there is an assignee) Attorney 11. □ English Translation Document (if applicable) 12. ☑ Information Disclosure ☑ Copies of IDS					
5. Oath or Declaration [Total Pages 3] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d)) (for a continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. Application Data Sheet. See 37 CFR 1.76						Statement (IDS)/PTO-1449 Citations 13. Preliminary Amendment 14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 15. Certified Copy of Priority Document(s) (if foreign priority is claimed) 16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. Other:					
or in an App ☐ Conti Prior app For CONTIN under Box 5	18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation-in-part (CIP) Of prior application No: Prior application information: Examiner Group / Art Unit: For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.										
•		·			NDENCE A						
⊠ Custon	© Customer Number or Bar Code Label 23599 PYROTET INCLUDES OF □ Correspondence address below										
Name											
Address		1-1-1									
City			Stat	e			Zip Code	e			
Country			Telephone				Fax	x			
Name (Pi	rint/Type)	Anthony J. Zela	ino		Registration No. (Attorney/Agent) 27, 969						
Signature	Signature				Date November 28, 2001						

Patent fees are subject to annual revision

Complete if Known Application Number November 28, 2001 Filing Date First Named Inventor Jun HATAKEYAMA et al. **Examiner Name** Group / Art Unit

TOTAL AMOUNT OF PAYMENT (\$) 908					Attorn	Attorney Docket No. KO			DJIM-436					
METHOD OF PAYMENT (check one)							FEE CALCULATION (continued)							
1. Depo	neit			oner is here and credit a					Fee	DITIONAL Large Entity Fee	Fee	Small Entity Fee	Fee Description	Fee
Acco	ount	13-3	3402					1	Code	(\$)	Code	(\$)	· · · · · · · · · · · · · · · · · · ·	Paid
Number							105 127	130 50	205 227	65 25	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or cover sheet.			
Deposit Account Millen, White, Zelano & Branigan, P C						139	130	139	130	Non-English specification				
Nam	е	L]	147	2,520	147	2,520	For filing a request for reexamination	
	Under 37	CFR 1	ional Fee f 16 and 1 1	7					112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
	See 37 C	FR 1.27		y status.					113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
2. 🛛	Payme	nt Enci	osea:						115	110	215	55	Extension for reply within first month	
⋈	Check		redit card		ney der		Other		116	390	216	195	Extension for reply within second month	
			EEE C	ALCULATIO					117	890	217	445	Extension for reply within third month	
1. 1	BASIC FI	LING F		-LOOLA III					118	1,390	218	695	Extension for reply within fourth month	
Large	Entity		Entity						128	1,890	228	945	Extension for reply within fifth month	
Fee Code		Fee Code		Fee Descri	ptio	n	Fee Paid		119	310	219	155	Notice of Appeal	
101	,	201	(\$) 355	Utility filing	foo		740	7	120	310	220	155	Filing a brief in support of an appeal	
106		201 206		Design filing			140		121	270	221	135	Request for oral hearing	
107		207		Plant filing 1				-	138	1,510	138	1,510	Petition to institute a public use proceeding	
108		208		Reissue filir		е			140	110	240	55	Petition to revive – unavoidable	
114	150	214	75	Provisional	filling	fee			141	1,240	241	620	Petition to revive – unintentional	
								_	142	1,240	242	620	Utility issue fee (or reissue)	
		S	SUBTOTAL	L (1)			(\$) 740		143	440	243	220	Design issue fee	
2. EXT	RA CLAII	V FEES	S						144	600	244	300	Plant issue fee	
				Extra	F	ee from	Fee		122	130	122	130	Petitions to the Commissioner	
Total Clair	ns 9	2	20** = [Claims 0	хĖ	elow	Paid		123	130	123	130	Petitions related to provisional applications	
Independer Claims	nt 5	<u> </u>	.3** =	2	×	84	= 168	7	126	180	126	180	Submission of Information Disclosure Stmt	
Multiple Dependent					×		= 0		581	40	581	40	Recording each patent assignment per property (times number of properties)	
Large Fee	Entity Fee	Fee	Fee	y Fee Des	crio	tion			146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code 103	(\$) 18	203	9 (\$)						149	710	249	355	For each additional invention to be	
103	18 80	203	9 40			ess of 20	excess of 3						examined (37 CFR § 1 129(b))	\vdash
102	270	204	135	•			ım, ıfnotpaio	-t	179	710	279	355	Request for Continued Examination (RCE)	
109	80	209	40	•	ue in	dependen	t claims over		169	900	169	900	Request for expedited examination of a design application	
110	18	210	9		ue cl	aıms ın ex	cess of 20 a	nd						
			SI	UBTOTAL (2)	(\$) 168		7	Other f	ee (speci	fy)			
ĺ									*Redu	ced by Ba	asıc Filin	g Fee Pa	aid SUBTOTAL (3) (\$) 0	
**or num	nber previo	usly paid	d, if greater	; For Reissu	9S, SE	ee above							(4) 0	

SUBMITTED BY				Cor	nplete (if applicable)
Name (Print/Type)	Anthony J. Zelano	Registration No Attorney/Agent)	27,969	Telephone	703-243-6333
Signature	5			Date	November 28, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.